Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (4557)	8/27/2001 6:45:23 PM
From: Miljenko Zuanic	Read Replies (1) \| Respond to of 52153

I am not sure that there is need for additional secondary end-points. Primary IA was safety or all adverse events and second primary IB was efficacy or avoidance rate for standard transfusion. While they did confirmed drug efficacy, no statistical and significant difference in adverse events (what was margin for difference: 20%, 30%, 50%...???) still does not prove that drug is completely safe. They have complete analysis (for each pts) and without any excuse they should come up with crude numbers. It remand me on ALXN, but....well Biova should know better what is going on. Miljenko